Picard Medical, Inc. (PMI)
| Market Cap | 21.83M |
| Revenue (ttm) | 5.47M +80.5% |
| Net Income | -28.28M |
| EPS | -0.54 |
| Shares Out | 92.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,530,901 |
| Open | 0.2680 |
| Previous Close | 0.3201 |
| Day's Range | 0.2424 - 0.2767 |
| 52-Week Range | 0.1100 - 13.6800 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About PMI
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the United States, Europe, and internationally. The company was incorporated in 2021 and is headquartered in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard ... [Read more]
Financial Performance
In 2025, Picard Medical's revenue was $4.94 million, an increase of 12.50% compared to the previous year's $4.39 million. Losses were -$27.00 million, 13.8% more than in 2024.
Financial StatementsNews
Picard Medical advances Emperor total artificial heart program
The company states: “Picard Medical (PMI) announced the successful completion of an acute in vivo implant study series using the Company’s next-generation Emperor Total Artificial Heart Platform at th...
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures —
PICARD MEDICAL, INC. Issues Letter to Shareholders
TUCSON, Ariz., May 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world's first and o...
Picard Medical / SynCardia Reports First Quarter 2026 Financial Results
– Gross profit turns positive; Company executes significant debt reduction – -- Responds to NYSE American continued listing notice - TUCSON, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc...
Picard Medical registers to sell 16.21M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 16.21M shares of common stock. The company is not selling any…
Picard Medical Registration statement: Registration filing
Picard Medical filed a registration statement on May 20, 2026, providing details about a securities offering with the SEC.
Picard Medical initiated with a Neutral at H.C. Wainwright
H.C. Wainwright initiated coverage of Picard Medical (PMI) with a Neutral rating without a price target Picard is a holding company that owns 100% of SynCardia Systems, the manufacturer of…
Picard Medical Quarterly report: Q1 2026
Picard Medical has published its Q1 2026 quarterly earnings report on May 15, 2026.
Picard Medical Earnings release: Q1 2026
Picard Medical released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Picard Medical Announces Pricing of $5 Million Offering
TUCSON, Ariz., May 05, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart a...
Picard Medical Registration statement: Registration filing
Picard Medical filed a registration statement on May 1, 2026, providing details about a securities offering with the SEC.
Picard Medical / SynCardia Recognizes Banner Health as Global Leader and Supporter in the Advancement of Total Artificial Heart Technology
Banner Health has performed more than 50 SynCardia Total Artificial Heart implants, establishing itself as a leading center in total artificial heart therapy Banner Health has performed more than 50 S...
Picard Medical / SynCardia Featured in Interview Series with The Mullings Group
– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development – TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, I...
Picard Medical Registration statement: Registration filing
Picard Medical filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
Picard Medical files to sell 11.82M shares of common stock, warrants
WestPark Capital is acting as placement agent.
Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto
TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the wo...
Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week
– Keynote to highlight innovation in artificial heart technology and expanding access for women with advanced heart failure –
Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week
Arizona industry event will highlight patient experience, advanced heart failure care, and the real-world impact of life-sustaining therapies Arizona industry event will highlight patient experience, ...
Picard Medical Earnings Call Transcript: Q4 2025
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 sales expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, positioning the therapy as the new standard of care for adult RRP.
Picard Medical Annual report: Q4 2025
Picard Medical has published its Q4 2025 annual report on March 25, 2026.
Picard Medical Earnings release: Q4 2025
Picard Medical released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Picard Medical Slides: Q4 2025
Picard Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 25, 2026.
Picard Medical’s SynCardia Total Artificial Heart used in succesful transplant
Picard Medical (PMI), parent company of SynCardia Systems, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, highlighted a case reported by…
Investors Sue Picard Medical for Hiding Stock Promotion Scheme
A class action lawsuit was filed against Picard Medical ($PMI) on February 2, 2026. Plaintiffs in the federal securities class action allege that they acquired Picard stock at artificially inflated…
Picard announces four-year bridge transplant with Syncardia artificial heart
Picard Medical (PMI) announced that a 29-year-old patient received a donor heart transplant after living for more than four years supported entirely by the SynCardia Total Artificial Heart. The patien...